Experience with prostaglandin analogues in primary open-angle glaucoma patients with cataract

PURPOSE. To investigate changes in macular thickness in patients with cataract and primary open-angle glaucoma (POAG) receiving prostaglandin analogues (PGA) during the perioperative period of phacoemulsification (PE), based on optical coherence tomography (OCT) data. METHODS. The study included 80 patients (126 eyes) divided into four groups: the control group (group 1) without POAG, and three POAG groups receiving different therapies: group 2 — tafluprost 0.0015% (Taflotan); group 3 — a fixed combination of brinzolamide 1% and timolol maleate 0.5% (Azarga); group 4 — Taflotan and Azarga. Macular thickness was assessed using OCT preoperatively, on postoperative day 7, and at 1 and 3 months in the central, superior, inferior, nasal, and temporal sectors. Statistical analysis was performed using nonparametric methods, including Pearson's χ² test, the Kruskal–Wallis H-test, and Fisher's F-test. RESULTS. One month postoperatively, the proportion of patients without pathological macular thickening exceeded 88% in all groups: 88.2% (group 1), 94.6% (group 2), 100% (group 3), and 90% (group 4) (p>0.05).At 3 months, retinal thickness remained above normal in two cases in group 1, two cases in group 2, none in group 3, and one case in group 4. CONCLUSION. The use of Taflotan during the perioperative period of PE in patients with cataract and POAG did not increase the risk of cystoid macular edema compared to the control and comparison groups.